Related Articles
00 / 00
Fox Chase Cancer Center holds the highest designation from the National Cancer Institute (NCI) as a Comprehensive Cancer Center. These elite centers are recognized for excellence in cancer treatment, research, prevention and education.
We are a member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the world’s leading cancer centers. NCCN centers are at the forefront of cancer diagnosis, treatment and supportive care, and lead the way in conducting groundbreaking research.
Fox Chase Cancer Center is accredited by The Joint Commission. Accreditation and certification is recognized nationwide as a symbol of quality that reflects an organization's commitment to meeting certain performance standards.
Our physicians and researchers frequently set new guidelines for breakthrough medicine and comprehensive care. We are a powerhouse for innovative research, with hundreds of clinical trials and basic research studies occurring at any one time.
The Fox Chase-Temple Bone Marrow Transplant Program is fully accredited by the Foundation for the Accreditation of Cellular Therapy (FACT)—the gold standard of excellence for blood and bone marrow transplant programs in the United States—and a participating provider in the National Marrow Donor Program (NMDP).
The Department of Radiation Oncology main campus, Buckingham, East Norriton, and the KOP-AUA facility have all received accreditation from the American College of Radiology (ACR).
Fox Chase Cancer Center has been named a Breast Imaging Center of Excellence by the ACR for mammography, breast ultrasound, ultrasound-guided biopsy, and stereotactic biopsy.
The Commission on Cancer (CoC) is a consortium of professional organizations dedicated to improving survival and quality of life for cancer patients through standard-setting, prevention, research, education, and the monitoring of comprehensive quality care. Learn More
Fox Chase Cancer Center is accredited by the National Accreditation Program for Breast Centers (NAPBC) of the American College of Surgeons. Learn More
Fox Chase Cancer Center has been recognized as a Quality Oncology Practice Initiative (QOPI®) Certified practice by the American Society of Clinical Oncology . The QOPI® Certification Program awards oncology practices that meet nationally recognized standards for cancer care. This certification reaffirms our commitment to providing patients with high-quality cancer care. QOPI and the QOPI Certification Program are projects dedicated to innovative quality improvement programs. For more information, please visit: https://practice.asco.org/quality-improvement/quality-programs.
The Lung Cancer Alliance (LCA) has named Fox Chase Cancer Center an LCA Screening Center of Excellence for Lung Cancer. This means Fox Chase lung cancer screening programs, such as low-dose CT scans, meet the alliance's standards for "Offering responsible screening and care."
Fox Chase Cancer Center has been designated as a National Pancreas Foundation Center by the National Pancreas Foundation (NPF), a nonprofit organization that provides hope for those suffering from pancreatic cancer, and other pancreas related diseases. Fox Chase is the only institution in the Philadelphia region to earn this designation.
Fox Chase is the first hospital in Pennsylvania and first acute specialty hospital in the U.S. to earn Magnet designation for excellence in nursing services through the American Nurses Credentialing Center, which renewed this honor in 2004, 2009, 2013, and again in 2018, making it the first hospital in Pennsylvania to have achieved four successful Magnet renewals.
Organizations that are accredited to the CEO Cancer Gold Standard™ demonstrate a commitment to improving the health and lives of their employees and their family members by maintaining a culture that fosters healthy lifestyles and provides support when a diagnosis of cancer becomes a reality. Fox Chase Cancer Center and other accredited members offer benefits and programs that lower the risk of cancer, detect it earlier, and provide access to high-quality treatment, including clinical trials.